Results 141 to 150 of about 6,940,670 (314)
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén +7 morewiley +1 more sourceTargeting p38α in cancer: challenges, opportunities, and emerging strategies
Molecular Oncology, EarlyView.p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.Angel R. Nebredawiley +1 more sourceInternational Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
Journal of Thoracic Oncology, 2011 W. Travis, E. Brambilla, M. Noguchi, A. Nicholson, K. Geisinger, Y. Yatabe, D. Beer, C. Powell, Gregory Riely, P. V. Van Schil, K. Garg, J. Austin, H. Asamura, V. Rusch, F. Hirsch, G. Scagliotti, T. Mitsudomi, R. Huber, Y. Ishikawa, J. Jett, M. Sanchez-Cespedes, J. Sculier, Takashi Takahashi, M. Tsuboi, J. Vansteenkiste, I. Wistuba, Pan‐Chyr Yang, D. Aberle, C. Brambilla, D. Flieder, W. Franklin, A. Gazdar, M. Gould, P. Hasleton, D. Henderson, B. Johnson, David H. Johnson, K. Kerr, K. Kuriyama, J. S. Lee, V. Miller, I. Petersen, V. Roggli, R. Rosell, N. Saijo, E. Thunnissen, M. Tsao, David Yankelewitz +47 moresemanticscholar +1 more sourceCorrelation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer
Molecular Oncology, EarlyView.PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova +10 morewiley +1 more sourceThe IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Journal of Thoracic Oncology, 2016 P. Goldstraw, K. Chansky, J. Crowley, Ramón Rami-Porta, H. Asamura, W. Eberhardt, A. Nicholson, P. Groome, A. Mitchell, V. Bolejack, Ramón Rami-Porta, D. Ball, D. Beer, R. Beyruti, F. Detterbeck, Wilfried Ernst Erich Eberhardt, J. Edwards, F. Galateau-Salle, D. Giroux, F. Gleeson, James Huang, C. Kennedy, Jhingook Kim, Y. T. Kim, L. Kingsbury, H. Kondo, M. Krasnik, K. Kubota, A. Lerut, G. Lyons, M. Marino, E. Marom, J. V. van Meerbeeck, T. Nakano, A. Nowak, M. Peake, T. Rice, K. Rosenzweig, E. Ruffini, V. Rusch, N. Saijo, P. Van Schil, J. Sculier, L. Shemanski, K. Stratton, Kenji Suzuki, Y. Tachimori, Charles F. Thomas, W. Travis, M. Tsao, A. Turrisi, J. Vansteenkiste, Hirokazu Watanabe, Yi‐Long Wu, P. Baas, J. Erasmus, S. Hasegawa, K. Inai, K. Kernstine, H. Kindler, L. Krug, K. Nackaerts, H. Pass, D. Rice, C. Falkson, P. Filosso, G. Giaccone, K. Kondo, M. Lucchi, M. Okumura, E. Blackstone, A. Cavaco, A. Barrera, Abal J. Arca, Parente I. Lamelas, Arnau A. Obrer, Guijarro R. Jorge, D. Ball, G. Bascom, B. Orozco, González M.A. Castro, M. Blum, D. Chimondeguy, V. Cvijanović, S. Defranchi, B. de Olaiz Navarro, Escobar I. Campuzano, Macía I. Vidueira, F. E. Araujo, André F. Garcia, K. Fong, Francisco G. Corral, C. S. Gonzalez, Freixinet J. Gilart, García L. Arangüena, García S. Barajas, P. Girard, T. Goksel, González M.T. Budiño, González G. Casaurrán, Gullón J.A. Blanco, Hernández J. Hernández, Hernández H. Rodríguez, Herrero J. Collantes, Iglesias M. Heras, Izquierdo J.M. Elena, E. Jakobsen, S. Kostas, León P. Atance, Núñez A. Ares, M. Liao, M. Losanovscky, G. Lyons, R. Magaroles, L. de Esteban Júlvez, Mariñán M. Gorospe, B. McCaughan, C. Kennedy, M. R. Íñiguez, Miravet L. Sorribes, Naranjo S. Gozalo, Álvarez C. de Arriba, Núñez M. Delgado, Padilla J. Alarcón, Peñalver J.C. Cuesta, J. Park, H. Pass, Pavón M.J. Fernández, M. Rosenberg, E. Ruffini, V. Rusch, Sánchez J. de Cos Escuín, Saura A. Vinuesa, Serra M. Mitjans, T. Strand, D. Subotic, S. Swisher, R. Terra, C. Thomas, K. Tournoy, P. Van Schil, M. Velasquez, Y. Wu, K. Yokoi +143 moresemanticscholar +1 more sourceBasroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Molecular Oncology, EarlyView.Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim +4 morewiley +1 more source
